Human TNFR1 / CD120a / TNFRSF1A Protein, Fc Tag (MALS verified)
分子别名(Synonym)
TNFR1, CD120a, TNFRSF1A, FPF, TBP1, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR55, TNFR60, p55, p60
表达区间及表达系统(Source)
Human TNFR1, Fc Tag (TN1-H5251) is expressed from human 293 cells (HEK293). It contains AA Leu 30 - Thr 211 (Accession # P19438).
Predicted N-terminus: Leu 30
蛋白结构(Molecular Characterization)

This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 47.9 kDa. The protein migrates as 55-60 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to different glycosylation.
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method / rFC method.
纯度(Purity)
>98% as determined by SDS-PAGE.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.


背景介绍
肿瘤坏死因子受体1(TNF-R1)亦称肿瘤坏死因子受体超家族成员1A(TNFRSF1A)、TNFAR、CD120a抗原,属于肿瘤坏死因子受体超家族。该受体包含1个死亡结构域和4个TNFR-Cys重复序列,是TNFSF2/TNF-α与同源三聚体TNFSF1/淋巴毒素-α的受体。衔接分子FADD可将caspase-8募集至活化受体处,由此形成的死亡诱导信号复合物(DISC)通过caspase-8的蛋白水解活化启动半胱天冬酶(天冬氨酸特异性半胱氨酸蛋白酶)的级联反应,从而介导细胞凋亡。TNF-R1还参与诱导非细胞毒性的肿瘤坏死因子效应,包括抗病毒状态激活及酸性鞘磷脂酶活化。TNFRSF1A基因缺陷是家族性希伯尼安热(FHF)的致病原因。
关键字: TNFR1;TNFR1蛋白;TNFR1重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。